Table 3.
Incremental Societal and Payer Costs (U.S. Dollars in 2005) per Follow-up for Intervention Group (CHA Plus Usual Care) and Control Group (Usual Care), Alameda County, California
| Perspective | Cost, $ | Incremental Cost, $ | Rate of 6-Month Follow Up | Increase in Rate of 6-Month Follow Up | Incremental Cost for Follow-Up, $ (95% CI) |
|---|---|---|---|---|---|
| Societal perspectivea | |||||
| Control | 77 | — | 0.32 | — | — |
| Intervention | 355 | 278 | 0.61 | 0.29 | 959 (787-1367) |
| Payer perspectiveb | |||||
| Control | 67 | — | 0.32 | — | |
| Intervention | 335 | 268 | 0.61 | 0.29 | 926 (754-1333) |
| Societal perspective by result of Pap test | |||||
| ASCUS/AGUS | |||||
| Control | 75 | — | 0.32 | — | — |
| Intervention | 347 | 272 | 0.57 | 0.25 | 1090 (813-1658) |
| LGSIL | |||||
| Control | 74 | — | 0.30 | — | — |
| Intervention | 374 | 300 | 0.64 | 0.34 | 882 (579-4584) |
| HGSIL | |||||
| Control | 105 | — | 0.43 | — | — |
| Intervention | 405 | 300 | 0.87 | 0.44 | 681 (486-1989) |
CI indicates confidence interval; Pap, Papanicolaou; ASCUS, atypical squamous cells of undetermined significance; AGUS, atypical glandular cells of undetermined significance; LGSIL, low-grade squamous intraepithelial lesion; HGSIL, high-grade squamous intraepithelial lesion.
a
Societal perspective includes all costs regardless who would bear them.
b
Payer perspective includes only the costs that the payer would bear.